Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven mycosis fungoides or Sezary syndrome
• * Any stage
• Measurable disease with 1 or more indicator lesions
• * Evaluable disease for erythrodermic patients only
• At least 2 weeks since prior therapy, if documented progressive disease (PD)
• At least 4 weeks since prior therapy, if best response achieved without clear evidence of PD
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• At least 3 months
• Hematopoietic:
• WBC at least 3,000/mm\^3
• Absolute granulocyte count at least 1,000/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin no greater than 2.2 mg/dL
• Renal:
• Creatinine no greater than 2.0 mg/dL
• Cardiovascular:
• No New York Heart Association class III or IV heart disease
• No cardiac pacemaker
• No clinically significant peripheral venous insufficiency
• Other:
• No other malignancy within the past 5 years except:
• * Treated squamous cell or basal cell skin cancer
• * Treated carcinoma in situ of the cervix
• * Surgically treated other cancer
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active infection
• HIV negative
• No poorly controlled diabetes mellitus
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• See Disease Characteristics
• Endocrine therapy:
• No concurrent steroids
• Radiotherapy:
• See Disease Characteristics
• No concurrent radiotherapy
• Surgery:
• Not specified
• Other:
• No other concurrent proven or investigational antineoplastic therapy